Both studies exclude individuals that either are treated with diabetes medication or have been diagnosed with diabetes despite GLP-1 RAs demonstrating their efficacy for reducing obesity-related adverse health effects in adults regardless of obesity status [41]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.